New radioactive tracer aims to spot hidden cancer in lymph nodes

NCT ID NCT04840472

Terminated Diagnosis Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a radioactive imaging agent called 111In-panitumumab in 28 people with head and neck cancer. The goal is to see if it can safely and accurately find cancer in lymph nodes compared to the standard dye method used during surgery. The study is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 111In-panitumumab (a radioactive imaging agent)
What this could lead to: If successful, this could lead to a more accurate, less invasive way to detect cancer spread to lymph nodes in head and neck cancer patients.
What could go wrong: This is a very early, small pilot study (Phase 1) that is currently suspended. The imaging agent may not work better than current methods, and there are unknown safety risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Locations

Stanford University

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.